Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Evommune's experimental eczema drug EVO756 failed to hit its primary and secondary endpoints in a mid-stage trial, prompting the company to scrap its atopic dermatitis program. Shares dropped 24% in aftermarket trading. The company plans to redirect EVO756 toward migraine prevention, where its safety profile remains encouraging.
Evommune pulls the plug on its eczema drug after a disappointing trial
Evommune announced it will not move forward with EVO756 as a treatment for atopic dermatitis after the drug failed to show a meaningful improvement on a standard eczema severity scale in a mid-stage trial. The news sent shares tumbling 24% in aftermarket trading.
The Phase 2 trial enrolled 121 adults with moderate-to-severe atopic dermatitis over a 12-week treatment period, with follow-up through week 14. EVO756 missed both primary and secondary endpoints across all doses tested.
By the Numbers
Why it matters: Despite the setback, Evommune isn't shelving EVO756 entirely — the company is pivoting to migraine prevention, citing a clean safety profile consistent with prior studies. With its balance sheet funded through 2029, Evommune says it has the runway to keep advancing its broader portfolio of chronic inflammatory disease programs.
